(Q36408727)

14 August 2017

1 reference

title

Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years (English)

1 reference

idiopathic pulmonary arterial hypertension

14 August 2017

0 references

0 references

author name string

Anna M Hackman

series ordinal

1

1 reference

PubMed ID

16506350

14 August 2017

Thomas E Lackner

series ordinal

2

1 reference

PubMed ID

16506350

14 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

68-94

1 reference

14 August 2017

1

1 reference

Hazards of diazoxide in pulmonary hypertension

14 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Coagulation and fibrinolytic parameters in patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Heart-lung transplantation for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Survival in primary pulmonary hypertension. Validation of a prognostic equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Bosentan for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Immediate and Long-term Hemodynamic and Clinical Effects of Sildenafil in Patients With Pulmonary Arterial Hypertension Receiving Vasodilator Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Efficacy and optimal dose of sildenafil in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.2006.26.1.68

10.1592/PHCO.2006.26.1.68

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16506350